NeuroThera Labs Inc. (TSXV: NTLX), a clinical-stage biotech company and majority-owned subsidiary of SciSparc Ltd., announced the closing of its acquisition of a majority stake in CliniQuantum Ltd., a private Israeli technology company specializing in quantum simulation and quantum Monte Carlo methods for clinical trial data analysis. The transaction, initially announced on March 10, 2026, and updated on May 27, 2026, involved the purchase of 56,375 ordinary shares representing approximately 54.01% of CliniQuantum's issued and outstanding shares.
As consideration, NeuroThera issued 56,600,000 common shares from treasury to the selling shareholders, valued at approximately $9,459,954.20 based on the 20-day volume-weighted average trading price. No cash was exchanged. Additionally, selling shareholders may receive earn-out payments of up to US$2,500,000, contingent on achieving milestones such as patent filings and fundraising proceeds, payable over three years. Finder's fees were satisfied with 2,829,999 common shares issued to arm's length finders.
CliniQuantum's platform applies quantum simulation and Monte Carlo methods to clinical trial data, aiming to improve precision by identifying patient subpopulations that respond to investigational therapies. NeuroThera believes this acquisition complements its existing CNS disorder programs and provides exposure to quantum technologies in life sciences. The transaction was deemed a “Reviewable Transaction” under TSXV Policy 5.3 due to involvement of non-arm's length parties, including Amitay Weiss, a director of SciSparc and Quantum X Labs Ltd., which holds the remaining 45.98% of CliniQuantum shares.
The Consideration Shares are subject to a TSXV Form 5D Escrow Agreement, with 10% released at closing and the remainder over 36 months. All shares are subject to a four-month-and-one-day hold period expiring October 2, 2026. The transaction received final TSXV acceptance and all necessary corporate approvals.
For more details, refer to the original press release on NewMediaWire and the Company's filings on SEDAR+.
